TB Update 2003 Jacqueline Peterson Tulsky, MD with thanks to Charles Daley, MD and Robert Jasmer, MD SF TB control and SFGH Pulmonary Department

Slides:



Advertisements
Similar presentations
HIV & TB. Worldwide TB is the most important opportunistic infection in HIV patients – its the commonest killer. Around 20 million people worldwide are.
Advertisements

TB & HIV Infection: Treatment
TB & HIV Infection: Treatment Your name Institution/organization Meeting Date International Standard 8, 13 TB & HIV Infection: Treatment Your name Institution/organization.
ISTC Training Modules 2008 Your name Institution/organization Meeting Date.
ART in HIV-Infected Patients with TB: Research Priorities Group II Facilitator: David Cohn Rapporteur: Soumya Swaminathan.
TB Disease and Latent TB Infection
ALOK SINHA Department of Medicine Manipal College of Medical Sciences Pokhara, Nepal.
Tuberculosis in Children: Prevention Module 10C - March 2010.
Continuity Clinic Tuberculosis. Continuity Clinic Objectives Know current epidemiologic trends in TB Know indications for testing for TB exposure and.
Why do we test? 1.We want to prevent an outbreak of Tuberculosis in our campus community 2.We want to find those that are affected and get them treated.
Initiating Antiretroviral Therapy in Treatment-Naive Patients Charles B. Hicks, MD Associate Professor of Medicine, Division of Infectious Diseases and.
Tuberculosis CAPT John Sanders CO, NMRC. 2 Outline Importance of TB Clinical Overview of TB Active vs. Latent TB Active TB diagnosis and treatment LTBI.
HIV and TB Co-infection North Dakota HIV Symposium May 19, 2010 David McNamara, M.D. Clinical Assistant Professor of Medicine University of North Dakota.
Unit 10 Treating the Dually Infected Patient: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
Why do we test? 1.We want to prevent an outbreak of Tuberculosis in our campus community 2.We want to find those that are affected and get them treated.
Tuberculosis in the Setting of HIV Infection
Tuberculosis Presented by Vivian Pham and Vivian Nguyen.
TB-HIV Update Asilomar 2007 Jacqueline Tulsky, MD SF AETC and SFGH Positive Health Program Francis J. Curry National TB Center Lisa Chen, MD Francis J.
Unit 5: IPT Isoniazid TB Preventive Therapy
Combination Antiretroviral Therapy for HIV Infection by Ormrat Kampeerawipakorn.
Chronic HIV Infection Clinical Manifestations Opportunistic Infections O.I. Prophylaxis.
2 About HIV: Teaching Tool. About HIV: A teaching tool © 2nd edition 2006 This tool was developed by the François-Xavier Bagnoud Center at the University.
The danger Numero Uno. That’s how it reaches you Unprotected sexual intercourse Intravenous drug abuse and shared needles From a HIV positive mother to.
TB and HIV Dr Mohern Archary Paediatric Infectious Disease Specialist Dept of Paediatrics and Child Health, UKZN.
Dr A.L. Pozniak Chelsea and Westminster Hospital London, UK
“Don’t tell me TB is under control!” Understanding TB
TUBERCULOSIS IN THE AGE OF HIV Dr. Terry Baker Physician National Chest Hospital.
Johns Hopkins Center for Tuberculosis Research
Use of 12 weekly doses of isoniazid and rifapentine for the treatment of latent tuberculosis − Connecticut , Kelley Bemis, MPH CDC/CSTE Applied.
HIV and TB Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health Program in Global Health, Division of Infectious Diseases David Geffen.
Determination of HIV Infection Among TB Patients in California, 2008 Darryl Kong 1, Jennifer Flood 1, Suzanne Marks 2, James Watt 1 1 California Department.
Tuberculosis Egan’s Chapter 22. Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 2 Tuberculosis (TB) The incidence of.
Nurses SOAR! Training Curricula Series For More Information and Inquiries:
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Anri Uys (MSc Pharmacology, BPharm NWU) Medicines Information Centre, Division of Clinical Pharmacology University of Cape Town.
TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.
TB/HIV management survey  Baseline audit in parallel with guidelines development process  Survey of clinician opinion and practice  Data collection.
Guidelines for the use of antiretroviral agents in HIV infections in Taiwan, revised in 2002 by Infectious Diseases Society of the ROC and Taiwan AIDS.
بسم الله الرحمن الرحيم. A 25 year old Saudi male applied to work as paramedic. He has no symptoms or history of contact with sick patients. His physical.
TO EVALUATE EARLY ANTIVIRAL RESPONSE AND SAFETY OF A DUAL BOOSTED PROTEASE INHIBITORS REGIMEN INCLUDING LOPINAVIR/r (LPV) PLUS AMPRENAVIR (AMP) OR FORTOVASE.
1 Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection, 2005 Applying CDC/ATS Guidelines in Your Clinical Practice Division of Tuberculosis.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Clinicopathologic Conference Advanced Update in HIV Medicine and Clinical Research October 1, 2009 Tammy M. Meyers, BA, MBBCh (WITS), FCPaed (SA), Mmed,
HIV/TB – Case Studies David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Health.
HIV/TB Integration in a Network of Voluntary Counseling/Testing Centers in HAITI Reynold Grand’Pierre MD, Marie Suze Jacquet MD, Jean W. Pape MD PEPFAR.
Efficacy and Safety of Maraviroc in Treatment- Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies.
Prophylaxis of Opportunistic Infections
Tuberculosis Trials Consortium (TBTC) Overview Completed, Ongoing, and Moxifloxacin Clinical Trials Kenneth G. Castro, M.D. Assistant Surgeon General,
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
TB Prevention and Control in Correctional and Detention Facilities Mark Lobato, MD Division of TB Elimination Centers for Disease Control and Prevention.
Predictors of Failure in Timely TB Treatment Completion, United States Carla Winston,PhD TB PEN Focal Point Open Forum June 5,
Tuberculosis in Children and Young Adults
Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.
TB-H V Co-infection by Dr. Ker Hong Bee 11. LEARNING OBJECTIVES To know & understand about TB-HIV co- infection in relation to:- – interaction & prevalence.
Depart. of Pulmonology R4 백승숙. 1. INTRODUCTION 2. BACKGROUND 3. DIAGNOSIS OF LATENT TB INFECTION 4. CHEMOPROPHYLAXIS 5. RISKS OF TUBERCULOSIS AND OF DRUG-INDUCED.
Tuberculosis in Children: Treatment and Monitoring Module 10B - March 2010.
Depart. of Pulmonology 백승숙. More than 80% of cases of tuberculosis in the United States –The result of reactivated latent infection –Nearly all these.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
Treatment of TB Disease
Tolerability of Isoniazid Preventive Therapy (IPT) in an HIV infected cohort
Treatment of Latent TB Infection (LTBI)
Pharmacokinetics: HIV Drugs
Predictors of antiretroviral treatment associated tuberculosis in Ethiopia: a nested case control study Nebiyu Mesfin, MD.
Dr Dawood Quiz questions.
بسم الله الرحمن الرحيم.
Marie Turner, M.D. Jo-Ann Keegan, R.N., M.S.N.
Tolerability of Isoniazid Preventive therapy Among HIV infected Cohort in Nigeria Folajinmi Oluwasina Strategic Information Unit AIDS Healthcare Foundation,
Anthony D Harries Ministry of Health, Malawi
Presentation transcript:

TB Update 2003 Jacqueline Peterson Tulsky, MD with thanks to Charles Daley, MD and Robert Jasmer, MD SF TB control and SFGH Pulmonary Department Or

Summary of Points 1. Latent Tuberculosis Infection (LTBI) Rifampin and Pyrazinamide (PZA) for 60 doses NOT RECOMMENDED ANY MORE 2. Active TB Treatment Avoid rifapentine Caution with twice weekly rifampin or rifabutin Stay calm in the face of immune reconstitution

TB Screening

Still important to do TB skin test on a 6-12 month routine basis Frequency tied to TB risk factors Symptom review, not x-ray for prior PPD positives No anergy panels

Quantiferon™ (QFT) Blood test looking for immune response to TB antigen Not approved for HIV-infected persons Not useful for diagnosing M. avium disease

Tuberculosis Screening Flowchart Evaluate for active TB At-risk person Tuberculin test + symptom review NegativePositive Chest x-ray NormalAbnormal Treatment not indicated Candidate for Rx of latent TB

Screening for Tuberculosis Chest Radiograph To screen for active TB you should still perform chest radiographs

Treatment of Latent Tuberculosis Infection (LTBI) ATS/CDC/IDSA Guidelines MMWR August 8, 2003

Isoniazid Therapy for LTBI HIV (+) Patients Location RegimensReduction in TB Haiti* 12 mo INH vs placebo83% Uganda6 mo INH vs placebo70% Zambia*6 mo INH 2 vs placebo 2 70% Kenya*6 mo INH vs placebo40% *These trials also included a TST (-) study arm in which no protection was observed

New Treatment of LTBI Regimen Duration Interval Comments (months) Isoniazid 9 Daily Preferred regimen Twice-wkly DOT necessary Isoniazid 6 Daily Not for HIV+ Twice-wkly DOT necessary Rifampin 4 Daily For INH-R ATS/CDC AJRCCM 2000;161:S221

What Happened to Rifampin and PZA for 60 doses for Treatment of LTBI????

An immigrant was tested and found to be PPD positive. The follow-up chest xray was normal and the patient was recommended for LTBI Denied hepatitis history or alcoholism Offered and accepted short course therapy with 60 doses of Rifampin/PZA Provided meds by DOT without complaints until last week of therapy Severe hepatitis requiring hospitalization

The patient had missed 2 clinic appointments during the course of treatment. No labs during the course of the Rifampin/PZA, should have had labs twice. “However, because the patient did not speak English, comprehension might have been a barrier.”

New Guidelines For Treatment of LTBI April, 2000 – Safety and efficacy of 60 doses of Rifampin and PZA lead to its recommendation October, 2000 – 1 patient dies, surveillance starts October, 2000 to June, 2002 – Cohort data collected on Rifampin/PZA patients

More Severe Hepatotoxicity

Rifampin and PZA Hepatoxicity In 30 months ending June, 2003: 48 cases of severe liver injury –37 recovered –11 died Most deaths had onset of liver injury in 2nd month 2 deaths in HIV positive persons CDC. MMWR, August 8, 2003

Rifampin/PZA Hepatotoxicity Hepatotoxicity RIF/PZA INH OR* (95% CI) N=307 N=282 Grade 1/2/3 45 (15%) 30 (11%) Grade 4† 9 (3%) 2 (1%) 8.05 ( ) Total 54 (18%) 32 (11%) 1.65 ( ) † Grade 4 toxicity - ALT ≥ 500 U/L or ≥ 250 with symptoms Jasmer et al. Ann Intern Med 2002;137:

Treatment of LTBI As of August, 2003 Rifampin or Rifabutin and PZA for 60 doses is contraindicated in all patients needing treatment for LTBI. (Rifampin or Rifabutin and PZA still okay for use in active TB with 1 or 2 other drugs.)

Treatment of LTBI (normal xray) HIV (–) persons –INH for 9 months is preferred over 6 HIV (+) persons –INH for 9 months HIV (–) and HIV (+) persons –Rifampin for 4 months

Treatment of LTBI Stable Fibrotic Scarring Acceptable regimens after active TB checked for include: –9 mos of INH* –4 months of rifampin  INH *preferred in HIV+ ATS/CDC AJRCCM 2000;161:S221

Treatment of LTBI Monitoring Elimination of routine baseline and follow- up liver function tests, except: –HIV infection –Others with increase risk hepatitis Emphasis is on clinical monitoring for signs and symptoms of drug side effect

Treatment of LTBI Monitoring for INH-induced Hepatitis Increased risk for hepatitis?* Yes Check baseline LFTs AbnormalNormal Monthly symptom review < 4 X upper limit of normal ≥ 4 X upper limit of normal No Hold INHGive INH and repeat LFTs periodically *HIV + Pregnant/postpartum Chronic liver disease Alcohol abuse

Treatment of Tuberculosis ATS, CDC, IDSA MMWR June 20, 2003/52(RR11);1-77

Active TB and HIV 1.Ensuring completion of therapy is essential 2.Treatment of TB/HIV is the same as for HIV negative persons except: lOnce-weekly rifapentine regimens cannot be used lTwice-weekly rifampin or rifabutin should not be used if the CD4 cell count is < 100 cells/ul 3.Be alert for drug interactions and paradoxical reactions

Ensuring Completion 15 Essential “The responsibility for successful treatment is clearly assigned to the public health program or private provider, not to the patient.” “It is strongly recommended that the initial treatment strategy utilize patient-centered case management with an adherence plan that emphasizes direct observation of therapy.”

Adherence Related Concepts Reach = Contact + Connect Easy to Contact /Hard to Connect ex: Homeless, IDUs, Street Youth, Inmates Hard to Contact/Easy to Connect ex: Undocumented immigrants, foreign language

Definitions Corollaries of “Hard-to-Reach” Provider-resistant patients Patient-resistant providers Patient-resistant systems and institutions * Rubel AJ and Garro LC. Public Health Reports, 1992;Vol 107

Treatment of Tuberculosis 1.Four drugs until sensitivities of cultures back (RIPE) 2.Intitial phase: 3 drugs until 2 months passes 3.Continuation phase: 2 drugs (usually ____ and ______) for 4 or 7 months Continuation phase usually becomes two or three times a week dosing…..UNLESS ADVANCED HIV

Treatment of Tuberculosis 1. RIPE – Rifampin/Isoniazid/Pyrazinamide/Ethambutol 2.Intitial phase: 3 drugs RIP 3.Continuation phase: 2 drugs RI Continuation phase usually becomes two or three times a week dosing…..UNLESS ADVANCED HIV

Treatment of HIV and TB Strongly recommend daily therapy if CD4 count <100 cells/ml HIV positive at any stage of infection - The continuation phase of treatment with weekly (yes weekly!) Rifapentine and INH NOT recommended

HIV and TB Drug-Drug Interactions Antiretroviral Drugs and TB drugs –NRTIs and NRSI okay –NNRTI and PIs some interaction due to liver metabolism

TB and HIV Drug-Drug Interactions Rifamycins Decrease in PIs and NNRTIs (L & S on speed) Rifampin > rifapentine > rifabutin Inducers of CYP3A Increase in serum concentration rifabutin* (L & S after lunch) Delavirdine and PIs Inhibitors of CYP3A *Rifampin and rifapentine are not substrates of CYP3A

TB and HIV Drug-Drug Interactions Protease Inhibitor Rifabutin Antiretroviral Regimen Dose Dose Nelfinavir, indinavir, 150 mg daily or nelfinavir-consider  to or amprenavir* 1500 mg q12hr 300 mg intermittently indinavir-consider  to 1000 mg q 8hrs amprenavir-no change Saquinavir* 300 mg daily or No change intermittently Ritonavir** 150 mg biw No change Lopinavir/ritonavir** 150 mg biw No change *+ 2 nucleosides ** + 2 nucleosides and/or NNRTI Burman and Jones. AJRCCM 2001;162:7

Treatment of HIV-related Tuberculosis Drug-Drug Interactions Antiretroviral Rifabutin Antiretroviral Regimen Dose Dose Nonnucleosides Efavirenz* mg daily or biw No change Nevirapine* 300 mg daily or intermittently No change Nucleosides 2-3 nucleosides 300 mg daily or biw No change PI + NNRTI Efavirenz or nevirapine 300 mg daily or biw Consider  + PI (except ritonavir) dose of indinavir * + 2 nucleosides Burman and Jones. AJRCCM 2001;162:7

HIV and TB Drug-Drug Interactions Rifampin-based regimens: –Ritonavir (600 mg bid) + Normal dose Rifampin (600 mg) –Efavirenz (800 mg daily) + Normal dose Rifampin (600 mg) –Do not use rifampin with low-dose ritonavir/PI combinations. Burman and Jones. AJRCCM 2001;162:7

35 year old woman with AIDS and CD4 of 45 developed active TB. Treated with 4 drug, then 3 drugs for 1 month by DOT. Thoughtful HIV specialist saw pt, they agreed together to start AZT/3TC/Indinavir. TB clinic changed patient from _________ to ________ and decreased the dose by half.

TB clinic changed patient from Rifampin 600mg to Rifabutin 150mg (half the normal dose).

In follow-up after 1 more month, patient decreased from 3 drugs to 2 drugs for TB. 4 months after initial diagnosis, the TB staff note patient coughing, losing weight and finally has a fever. Chest x-ray shows recurrent TB infection. What is the key question in this patient’s medication history?

ARE YOU STILL TAKING YOUR ARV THERAPY? WHY IS THIS SO IMPORTANT?

TB and HIV Drug-Drug Interactions Protease Inhibitor Rifabutin Antiretroviral Regimen Dose Dose Nelfinavir, indinavir, 150 mg daily or or amprenavir* 300 mg intermittently indinavir-consider to 1000 mg q 8hrs SO, if NOT TAKING Indinavir, Rifabutin dose IS TOO LOW. TB resistance can develop within 30 days if on single drug therapy!! MUST COORDINATE HIV and TB MEDS

Treatment of HIV and TB On HAART No Yes CD4 <200 CD CD4 > 350 Begin HAART in 2 wks Start 4-drug TB regimen Begin HAART in 2 mos No HAART Continue and adjust dosages

Paradoxical Reactions Immune Restoration Syndromes Paradoxical reaction - transient worsening of condition after initiation of treatment; not the result of treatment failure Common manifestations ( new or worsening ): –Adenopathy –Pulmonary infiltrates –Serositis –Cutaneous or CNS lesions (spots)

Paradoxical Reaction Worsening Radiograph

Paradoxical Reactions Immune Restoration Syndromes Three case series: 6-36% occurrence Median 15 days after starting ARV therapy Most patients have advanced HIV disease –median CD4 cell count of 35 cells/ mm 3 –median viral load > 500,000 copies/ml

Paradoxical Reactions Management Diagnosis of exclusion –Treatment failure, drug toxicity, other infection –Often start treatment for presumed relapse or reactivation Severe reactions –Corticosteroids or –Hold ARV therapy (Controversial)

Extra pulmonary TB Disease More common as HIV advances Be sure to rule out pulmonary disease Guidelines recommend 9-12 months in patients with: –Meningeal TB Corticosteroids may be useful in some forms of extrapulmonary TB

Summary of Points 1. Latent Tuberculosis Infection (LTBI) Rifampin and PZA for 60 doses NOT RECOMMENDED ANY MORE 2. Active TB Treatment Avoid rifapentine Caution with twice weekly rifampin or rifabutin Stay calm in the face of immune reconstitution

TB Update 2003 or